This data visualization was updated in September 2018 with new data.
As of June 2018, an estimated 30 new nontraditional products1 with the potential to treat or prevent serious bacterial infections are in clinical development. Below is a snapshot of the current nontraditional products pipeline, based on publicly available information and informed by external experts. It is updated periodically as products advance or are known to drop out of development. Because this list is updated periodically, endnote numbers may not be sequential.
Please contact email@example.com with additions or updates.
Note: The following drugs have been removed from the pipeline. They will be included in future updates if development resumes:
June 2018: ASN100, GEN 004, Group B Streptococcus vaccine, and VLA84 (IC84) were removed because they were no longer included in the research and development pipeline on the company’s website.